Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk

Area of Science:

• Cardiology
• Biochemistry

Background:

• Low-density lipoprotein-cholesterol (LDL-C) is a primary driver of atherosclerotic cardiovascular disease (ASCVD).
• Lowering LDL-C is the cornerstone of ASCVD risk reduction in primary and secondary prevention.
• Statin therapy, while foundational, has limitations in adherence and achieving target LDL-C levels for many patients.

Purpose of the Study:

• To review novel and emerging therapeutic strategies for further reducing LDL-C levels.
• To highlight the need for more effective LDL-C lowering beyond current statin treatments.

Main Methods:

• Review of current literature on emerging LDL-C lowering targets.
• Discussion of specific molecular targets including ATP-citrate lyase, PCSK9, ANGPTL3, and CETP.

Main Results:

• Multiple therapeutic targets beyond statins show promise for significant LDL-C reduction.
• Emerging therapies offer potential for enhanced atherosclerotic cardiovascular disease risk management.

Conclusions:

• Newer agents targeting ATP-citrate lyase, PCSK9, ANGPTL3, and CETP represent promising advancements in LDL-C management.
• These novel approaches are crucial for addressing residual cardiovascular risk in patients inadequately managed by statins alone.